Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2023-01-16 Regulatory Filings
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
Xlife Sciences-Portfoliogesellschaft startet Projekt zur Erforschung einer potenziellen Therapie gegen Amyotrophe Lateralsklerose (ALS)
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by the structure, 'Ende der Medienmitteilungen', and the presence of an EQS News ID) announcing a new research project by a portfolio company regarding a potential ALS therapy. It contains general company information, quotes, and a financial calendar listing future reports (Annual Report, AGM, Half-year report). This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific transaction report, falls best under the general category for regulatory announcements or miscellaneous news releases that don't fit elsewhere. Since it is a news release about operational/research progress and includes a financial calendar, it is most appropriately classified as a Regulatory Filing (RNS) as the general catch-all for non-standard, yet official, company communications, or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a report, which it is not doing here. Given the content is a general operational update/news release, RNS is the most suitable fit among the provided options, as it is not an ER, CT, or a specific financial report.
2023-01-16 German
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies
Regulatory Filings Classification · 1% confidence The document is a press release dated December 1, 2022, detailing a new exclusive license agreement between Xlife Sciences' portfolio company Lysatpharma and the joint venture Novaxomx regarding research and product development in biosurgical treatment therapies. It contains operational updates, quotes from management, and a financial calendar listing future reports (Annual Report 2022, Ordinary AGM 2023, Half-Year Report 2023). This content is a general corporate announcement about business operations and strategic progress, not a specific regulatory filing like a 10-K, an Earnings Release (ER), or a formal report itself. Since it is a general news release announcing business developments and does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements that do not fit elsewhere, often used for press releases disseminated via news services like EQS.
2022-12-01 English
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies
Regulatory Filings Classification · 1% confidence The document is a press release dated December 1, 2022, announcing a strategic licensing agreement between portfolio company Lysatpharma and joint venture Novaxomx regarding exosome technology for biosurgical treatments. This type of announcement, detailing operational progress, partnerships, and R&D milestones, is characteristic of a general corporate update or news release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory/news fallback category, RNS (Regulatory Filings), as it serves as a broad announcement mechanism for material, non-standardized news.
2022-12-01 English
Portfoliogesellschaft Lysatpharma und Joint-Venture Novaxomx starten Forschung und Produktentwicklung im Bereich biochirurgischer Behandlungstherapien
Regulatory Filings Classification · 1% confidence The document is a press release dated 01.12.2022, announcing a significant business development: a licensing agreement between two portfolio companies regarding research and product development in bio-surgical therapies. It contains quotes from management, details about the technology, and a financial calendar. This type of announcement, detailing strategic operational progress rather than routine financial results (like an ER or IR) or mandatory regulatory filings (like 10-K), is best classified as a general business update or regulatory announcement. Since it is a formal announcement released via a news service (indicated by the EQS News ID and structure), and it doesn't fit perfectly into specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous official announcements not covered elsewhere.
2022-12-01 German
alytas therapeutics collaborates with spin-off from the German Diabetes Center
Regulatory Filings Classification · 1% confidence The document is a press release dated November 28, 2022, detailing a research collaboration between Xlife Sciences' portfolio company alytas therapeutics and CureDiab Metabolic Research. It contains general corporate news, quotes from management, and a financial calendar listing future events like the Annual Report and Ordinary AGM. The content is not a formal regulatory filing like a 10-K, nor is it a specific financial report (like ER or IR). It is a general corporate announcement distributed via a news service (EQS News Service). Since it is a general corporate news release that doesn't fit the specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which often serves as a catch-all for official, non-standard announcements.
2022-11-28 English
alytas therapeutics collaborates with spin-off from the German Diabetes Center
Regulatory Filings Classification · 1% confidence The document is a press release announcing a research collaboration between Xlife Sciences' portfolio company alytas therapeutics and CureDiab Metabolic Research. It contains general business updates, quotes from management, and a financial calendar listing future reporting dates (Annual Report, AGM, Half-Year Report). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific report (AR, IR). Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Change (CAP), and it is not merely announcing the publication of another report (RPA), it falls best under the general regulatory announcement category, which is RNS, as it is a news release disseminated to the market.
2022-11-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.